# EGFR T790M

> genetic variant

**Wikidata**: [Q25100112](https://www.wikidata.org/wiki/Q25100112)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/T790M)  
**Source**: https://4ort.xyz/entity/egfr-t790m


## References

1. [CIViC database](https://civic.genome.wustl.edu/links/variants/34)
2. [Rociletinib in EGFR-mutated non-small-cell lung cancer](https://civic.genome.wustl.edu/links/evidence/646)
3. [A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity](https://civic.genome.wustl.edu/links/evidence/278)
4. [AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer](https://civic.genome.wustl.edu/links/evidence/963)
5. [AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer](https://civic.genome.wustl.edu/links/evidence/965)
6. [Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib](https://civic.genome.wustl.edu/links/evidence/966)
7. [Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC](https://civic.genome.wustl.edu/links/evidence/762)
8. [Osimertinib: First Global Approval](https://civic.genome.wustl.edu/links/evidence/1592)
9. [Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.](https://civic.genome.wustl.edu/links/evidence/1867)
10. [Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain](https://civic.genome.wustl.edu/links/evidence/1397)
11. [EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients](https://civic.genome.wustl.edu/links/evidence/2157)
12. [Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.](https://civic.genome.wustl.edu/links/evidence/2162)
13. [BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models](https://civic.genome.wustl.edu/links/evidence/2163)
14. [Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models](https://civic.genome.wustl.edu/links/evidence/2164)
15. [BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models](https://civic.genome.wustl.edu/links/evidence/2165)
16. [Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC](https://civic.genome.wustl.edu/links/evidence/277)
17. [In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer](https://civic.genome.wustl.edu/links/evidence/967)
18. [PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib](https://civic.genome.wustl.edu/links/evidence/2161)
19. [EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance](https://civic.genome.wustl.edu/links/evidence/6006)
20. [EGFR T790M resistance mutation in non small-cell lung carcinoma](https://civic.genome.wustl.edu/links/evidence/238)
21. [EGFR mutation and resistance of non-small-cell lung cancer to gefitinib](https://civic.genome.wustl.edu/links/evidence/239)
22. [Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma](https://civic.genome.wustl.edu/links/evidence/1667)
23. [Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors](https://civic.genome.wustl.edu/links/evidence/240)
24. [Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers](https://civic.genome.wustl.edu/links/evidence/1391)
25. [Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors](https://civic.genome.wustl.edu/links/evidence/1863)
26. [BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models](https://civic.genome.wustl.edu/links/evidence/2160)
27. [Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain](https://civic.genome.wustl.edu/links/evidence/2158)
28. [The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis](https://civic.genome.wustl.edu/links/evidence/369)
29. [Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients](https://civic.genome.wustl.edu/links/evidence/370)
30. CIViC database
31. [OpenAlex](https://docs.openalex.org/download-snapshot/snapshot-data-format)